Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

2.960 -0.030 (-1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024
ALZN stock results show that Alzamend Neuro missed analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024
Alzamend Neuro just reported results for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024
ALZN stock results show that Alzamend Neuro beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for  
Via Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Shares of Symbotic Inc. (NASDAQ: SYM) surged in pre-market trading after the company reported better-than-expected fourth-quarter sales results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
Alzamend Neuro Inc (NASDAQ: ALZN) has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for  
Via Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA for the initiation of study AL001-PTSD01, a Phase 2A plasma/brain pharmacokinetics study of... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The... 
Via Benzinga
Topics Stocks
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Crude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.14% to 32,788.73 while the NASDAQ rose 0.98% to 12,766.33. The... 
Via Benzinga
Topics Stocks
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
From Alzamend Neuro, Inc.
Via Business Wire
Why Alzamend Neuro (ALZN) Stock Is Nosediving Today
Alzamend Neuro Inc (NASDAQ: ALZN) shares are trading lower by 31.2% to $0.12 Monday morning after the company announced a reverse stock split. What Happened? 
Via Benzinga
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.